<DOC>
	<DOCNO>NCT00931463</DOCNO>
	<brief_summary>The investigator hypothesize follow virological failure standard NNRTI+2N ( T ) RTI regimen second-line antiretroviral therapy consist ritonavir-boosted lopinavir 2N ( T ) RTIs offer comparable efficacy provide ritonavir-boosted lopinavir raltegravir . The study conduct 96-weeks primary endpoint analyze 48-weeks . The primary endpoint virological : comparison virological suppression plasma &lt; 200 copies/mL randomize arm 48 week . Secondary exploratory endpoint include virological , immunological , safety , clinical , metabolic , drug adherence , drug resistance quality life .</brief_summary>
	<brief_title>A Trial 2 Options Second Line Combination Antiretroviral Therapy Following Virological Failure Standard Non-nucleoside Reverse Transcriptase Inhibitor ( NNRTI ) +2N ( ) RTI First Line Regimen</brief_title>
	<detailed_description>In HIV-infected subject virologically fail first-line antiretroviral therapy comprise 2N ( ) RTI + NNRTI regimen second-line therapy incorporate ritonavir-boosted lopinavir raltegravir provide comparable ( i.e. , non-inferior ) antiretroviral efficacy 48 week regimen contain ritonavir-boosted lopinavir 2-3N ( ) RTIs . Eligible patient randomise one two arm : I. ritonavir boost lopinavir ( LPV/r ) 200mg/50mg 4 tab daily 2 tab twice daily + 2-3N ( ) RTIs II . ritonavir boost lopinavir ( LPV/r ) 200mg/50mg 4 tab daily 2 tab twice daily + raltegravir 400 mg twice daily The primary objective study compare virological efficacy two strategy measure proportion participant HIV RNA &lt; 200 copies/mL 48 week randomisation . Secondary objective include virological , immunological , safety antiretroviral therapy endpoint . Exploratory endpoint include clinical , metabolic , drug resistance , medication adherence quality life endpoint .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>1 . HIV1 positive license diagnostic test 2 . Aged 16 year old ( minimum age determine local regulation legal requirement dictate ) 3 . Have receive first antiretroviral regimen consist NNRTI plus 2N ( ) RTIs least 24 week 4 . No change antiretroviral therapy within 12 week prior screen 5 . Failed firstline NNRTI + 2N ( ) RTI combination therapy accord virological criterion define two consecutive ( least 7 day apart ) HIV RNA result great 500 copies/mL 6 . No prior current exposure HIV protease inhibitor and/or HIV integrase inhibitor 7 . Able provide write informed consent 1 . The following laboratory variable : absolute neutrophil count ( ANC ) &lt; 500 cells/microlitres hemoglobin &lt; 7.0 g/decilitres platelet count &lt; 50,000 cells/microlitres ALT great 5 x ULN 2 . Pregnant nursing mother 3 . Participants active viral hepatitis B infection define presence serum hepatitis B surface antigen 4 . Use immunomodulators within 30 day prior screen 5 . Use prohibit medication ( rifampicin , midazolam , triazolam , cisapride , pimozide , amiodarone , dihydroergotamine , ergotamine , ergonovine , methylergonovine , astemizole , terfenadine , vardenafil , St. John 's wort ) 6 . Intercurrent illness require hospitalization 7 . Active opportunistic disease adequate control opinion site Principal Investigator 8 . Participants current alcohol illicit substance abuse opinion site Principal Investigator might adversely affect participation study 9 . Participants deem site Principal Investigator unlikely able remain followup protocoldefined period</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>second line therapy</keyword>
	<keyword>combination antiretroviral therapy</keyword>
	<keyword>first-line failure</keyword>
	<keyword>AIDS</keyword>
	<keyword>treatment experience</keyword>
</DOC>